trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Catch-up vaccination schedules safely mitigate missed doses of infant pneumococcal vaccines.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
4 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that catch-up vaccination schedules safely mitigate missed doses of infant pneumococcal vaccines?

Yes. Clinical trials consistently demonstrate that catch-up vaccination schedules for pneumococcal conjugate vaccines are safe, well tolerated, and immunogenic in children who missed initial doses.

Verdict: SUPPORTED · 4 sources for, 0 against · Last checked

The analysis

The retrieved literature includes multiple clinical trials (such as papers 5, 7, 8, and 10) explicitly evaluating catch-up vaccination regimens for pneumococcal conjugate vaccines across various age groups. These studies uniformly report that catch-up schedules are safe, well tolerated, and elicit robust immune responses, directly supporting the claim.

Evidence for · 4
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).
2022
Demonstrates that catch-up vaccination with V114 is generally well tolerated and immunogenic in children with incomplete or no prior PCV immunization.
Get citation
Banniettis, N., Wysocki, J., Szenborn, L., Phongsamart, W., Pitisuttithum, P., Rämet, M., Richmond, P., Shi, Y., Dagan, R., Good, L., Papa, M., Lupinacci, R., McFetridge, R. D., Tamms, G., Churchill, C., Musey, L., & Bickham, K. (2022). A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).. doi.org. https://doi.org/10.1016/j.vaccine.2022.09.003

See more details
More for · 3
A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age
2023
Shows that PCV13 administered as a catch-up regimen in older infants and children effectively elicits strong immune responses and is well tolerated.
Get citation
Chu, K., Hu, Y., Pan, H., Wu, J., Zhu, D., Young, M. M., Luo, L., Yi, Z., Giardina, P., Gruber, W., Scott, D., & Watson, W. (2023). A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age. doi.org. https://doi.org/10.1080/21645515.2023.2235926

Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study
2015
Finds that a 2-dose catch-up vaccination with 10-valent pneumococcal conjugate vaccine in the second year of life is safe and immunogenic.
Get citation
Dicko, A., Dicko, Y., Barry, A., Sidibé, Y., Mahamar, A., Santara, G., Dolo, A., Diallo, A., Doumbo, O., Shafi, F., François, N., Yarzábal, J., Strezova, A., Borys, D., & Schuerman, L. (2015). Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study. doi.org. https://doi.org/10.1080/21645515.2015.1016679

Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules.
2018
Reports that catch-up and alternative pneumococcal conjugate vaccine schedules exhibit satisfactory safety and immunogenicity profiles.
Get citation
Moïsi, J., Yaro, S., Kroman, S., Gouem, C., Bayané, D., Ganama, S., Meda, B., Nacro, B., Njanpop-Lafourcade, B., Ouangraoua, S., Ouédraogo, I., Sakandé, S., Sawadogo, F., Zida, S., Ouédraogo, J., & Gessner, B. (2018). Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules.. doi.org. https://doi.org/10.1093/jpids/piy075

Receipt History
first checked04 Aug 2026
judged → SUPPORTED · 8204 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work